Medical Article

Apogee Therapeutics brings AbbVie a long-acting antibody ready for Phase 3 testing in atopic dermatitis, also called eczema. This therapy’s pipeline in a product potential includes respiratory conditions such as asthma — as a monotherapy and as part of novel drug combinations. The post AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge…

Eli Lilly made good on its threat to withhold 340B drug discounts from hospitals that refused to submit claims data. Hospital groups are calling the policy unlawful, arguing that the company has no legal authority to create its own compliance requirements for a federal program. The post Hospitals Cry Foul After Eli Lilly Withholds 340B…

Abarca Health and LucyRx plan to combine to build a larger independent PBM serving more than 9 million members. The post Abarca Health and LucyRx to Combine to Scale Independent PBM Model appeared first on MedCity News.

Alternative health plan designs represent much more than a passing trend. They are actively testing long-standing assumptions about how benefits should be structured, delivered, and experienced. The post Alternative Health Plan Designs Are Reshaping Employer Benefits appeared first on MedCity News.

For governments and health systems, monoclonal antibodies represent not just another drug class, but a strategic shift toward precision prevention. The post Passive Immunization: The Expanding Role of Monoclonal Antibodies in Preventive Medicine appeared first on MedCity News.

We’re entering uncharted territory if bad actors can both launch zero-days and exploit unaddressed backdoors with new efficiency. This is why teams need to unify their network structure and better forecast what they’re up against. The post Preparing Healthcare Networks For The Vulnerability Flood appeared first on MedCity News.